Prelude Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Prelude Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-700	Closed	-$319K	–	1960
2021 Q1	$319K	Buy	+700	New	+$334K	0.01%	1110
2019 Q2	–	Sell	-15,000	Closed	-$4.11M	–	2143
2019 Q1	$4.11M	Hold	15,000	–	–	0.23%	73
2018 Q4	$3.36M	Buy	+15,000	New	+$3.52M	0.22%	83

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Prelude Capital Management's TMO Position: Q2 2026 in Review

Prelude Capital Management increased its Thermo Fisher Scientific (TMO) stake by 588% in Q2 2026, buying an estimated $2.36M and bringing the position to 5,752 shares worth $2.88M. The position accounts for 0.21% of the portfolio, ranked #119.

Prelude Capital Management first reported a position in TMO in Q2 2013 and has held it in 33 quarters since. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Prelude Capital Management held 5,752 shares of Thermo Fisher Scientific worth $2.88M as of Q2 2026.
Prelude Capital Management bought 4,916 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.36M.
Thermo Fisher Scientific made up 0.21% of Prelude Capital Management's portfolio in Q2 2026, its #119 holding.
Prelude Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 33 quarters since.
2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.